Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-trial results buried in Merck’s 300-page 10-K can dictate the future of therapies like Keytruda, yet those details are easy to miss. Add patent-expiration tables, FDA correspondence, and worldwide vaccine sales data and you have one of the most complex disclosure packages in the market. That’s why professionals searching for Merck & Co. SEC filings explained simply come here first.
Stock Titan’s AI reads every Merck & Co. annual report 10-K simplified, Merck & Co. quarterly earnings report 10-Q filing, and Merck & Co. 8-K material events explained the moment they hit EDGAR. Our technology pinpoints where management discusses pipeline milestones, litigation reserves, or emerging biosimilar risks so you can act quickly instead of parsing footnotes.
- Get instant alerts on Merck & Co. Form 4 insider transactions real-time and spot trading patterns before key data releases.
- See concise takeaways from every Merck & Co. proxy statement executive compensation to understand how R&D targets drive bonuses.
- Dive into patent expiry schedules and regional vaccine sales in seconds with AI-generated tables.
Whether you’re monitoring Merck & Co. insider trading Form 4 transactions, comparing quarter-over-quarter oncology revenue, or simply understanding Merck & Co. SEC documents with AI, our platform delivers. Each document arrives with a plain-language summary, key-metric extraction, and cross-linking to prior periods for seamless Merck & Co. earnings report filing analysis. No more hunting through exhibits—just clean insights updated in real time.
Merck & Co., Inc. is launching a multi-tranche senior notes offering, including floating-rate notes linked to Compounded SOFR and several fixed-rate series, to raise capital for general corporate purposes. The company may also use part of the proceeds to help fund its proposed all-cash acquisition of Cidara Therapeutics for
The notes will be unsecured senior obligations of Merck, structurally subordinated to debt at its subsidiaries, and will not be listed on any exchange. Several series, including the floating-rate notes, carry a special mandatory redemption at
Merck & Co., Inc. (MRK) reported an insider transaction on Form 4. Chief Communications & Public Affairs Officer Cristal N. Downing sold 7,085 shares of Merck common stock at $87 on 11/10/2025 (transaction code S), and reported 0 shares beneficially owned following the sale.
The filing indicates direct ownership for the transaction. The document was signed by an attorney-in-fact on behalf of the reporting person.
Merck & Co., Inc. (MRK) reported a Form 144 notice for a proposed sale of up to 7,085 shares of common stock, with an aggregate market value of $616,395.00. The planned sale is listed for the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of November 10, 2025.
The shares to be sold were acquired via restricted stock vesting under a registered plan in two tranches: 2,361 shares on 01/17/2025 and 4,724 shares on 01/27/2025. Shares outstanding are shown as 2,482,022,536, which is a baseline figure and not the amount being sold.
Merck & Co., Inc. (MRK) disclosed an insider transaction by EVP, Chief Information & Digital Officer David Michael Williams. He sold 8,614 shares of common stock on November 3, 2025 at a weighted average price of $83.5895, with trades executed between $83.54 and $83.62. Following the sale, he directly owned 24,578.031 shares. The filing notes that holdings include shares acquired through dividend reinvestment.
MRK filed a Form 144 indicating a proposed sale of 8,614 shares of common stock with an aggregate market value of $720,039.95.
The notice lists Morgan Stanley Smith Barney LLC as the broker, the NYSE as the exchange, and an approximate sale date of November 3, 2025. The shares were acquired through restricted stock vesting under a registered plan on multiple dates.
Shares outstanding were 2,497,783,211.
Merck & Co., Inc. (MRK) furnished an 8-K under Item 2.02, providing an earnings press release for the third quarter of 2025 as Exhibit 99.1 and additional supplemental materials as Exhibit 99.2. The company states this information is being furnished and is not deemed filed under Section 18 of the Exchange Act.
The filing also includes Exhibit 104 (Cover Page Interactive Data File). Merck’s common stock trades on the NYSE under MRK.
Christine E. Seidman, a director of Merck & Co., Inc. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 100 common shares and the acquisition of 96.8069 phantom stock units that correspond to 96.8069 underlying common shares at a reported price of $83.93 per share. After the reported transactions, the reporting person beneficially owned 18,775.7818 shares. The filing explains phantom stock units are to be settled 100% in cash upon the reporting person’s termination of service per the Plan for Deferred Payment of Directors’ Compensation, and that holdings include shares acquired via dividend reinvestment. The form was signed by an attorney-in-fact on 10/02/2025.
Thomas H. Glocer, a director of Merck & Co., Inc. (MRK), reported transactions dated 09/30/2025. The filing shows a disposition of 5,100 shares of Merck common stock in the non-derivative section. In the derivative section, Mr. Glocer acquired 580.8412 phantom stock units on the same date; those units are to be settled 100% in cash upon his termination of service under the referenced deferred compensation plan. The phantom units represent 580.8412 underlying common shares with an indicated price of $83.93, and the report lists 105,645.8965 shares beneficially owned following the transactions. The form is signed by an attorney-in-fact for Mr. Glocer on 10/02/2025. The filing notes that holdings include shares acquired through dividend reinvestment.
FAQ
What is the current stock price of Merck & Co (MRK)?
What is the market cap of Merck & Co (MRK)?
